TheraRadar

Pharma Intelligence, Simplified

Landscape → CNS

ADHD

161 clinical trials

40 active
/
161 total (since 2015)
7
Phase 1 Active
26 total
12
Phase 2 Active
40 total
11
Phase 3 Active
65 total
15
Phase 4 Active
43 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Otsuka Pharmaceutical Co., Ltd. 4 0 0
Otsuka Pharmaceutical Development & Commercialization, Inc. 2 9 1
Boehringer Ingelheim 1 0 0
Bazelet Nehushtan LtD. 1 0 0
Shanghai Ark Biopharmaceutical Co., Ltd. 1 0 0
Supernus Pharmaceuticals, Inc. 0 9 4
Takeda 0 9 1
Aevi Genomic Medicine, LLC, a Cerecor company 0 5 0
Sumitomo Pharma America, Inc. 0 5 0
Cingulate Therapeutics 0 3 1
Tris Pharma, Inc. 0 4 0
Neurocentria, Inc. 0 1 2
Pfizer 0 0 3
NCT07086313 RECRUITING
A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
Otsuka Pharmaceutical Co., Ltd. n=315
NCT07087327 RECRUITING
A Long-term Trial of EB-1020 in Pediatric Patients With ADHD
Otsuka Pharmaceutical Co., Ltd. n=180
NCT06973577 RECRUITING
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Otsuka Pharmaceutical Development & Commercialization, Inc. n=308
NCT06931080 RECRUITING
Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients
Otsuka Pharmaceutical Co., Ltd. n=630
NCT06926829 RECRUITING
A Long-term Trial of EB-1020 in Adult Patients With ADHD
Otsuka Pharmaceutical Co., Ltd. n=180
NCT05842330 RECRUITING
Benefits of ADHD Treatment in Detained People
Stéphanie Baggio n=150
NCT04704687 RECRUITING
Clinical Efficacy and Long Term Effects of Transcranial Direct Current Stimulation (tDCS) in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
Centre Hospitalier Universitaire, Amiens n=150
NCT04240756 ACTIVE NOT RECRUITING
Treating Parents with ADHD and Their Young Children Via Telehealth: a Hybrid Type I Effectiveness-Implementation Trial
University of Maryland, College Park n=240
NCT05832489 RECRUITING
EEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood Disorders
University Hospital, Strasbourg, France n=80
NCT06359899 NOT YET RECRUITING
A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD
Shanghai Ark Biopharmaceutical Co., Ltd. n=50
NCT04216186 RECRUITING
Role of Coenzyme Q in ADHD in Children
Sherief Abd-Elsalam n=40
NCT05972044 COMPLETED
A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
Axsome Therapeutics, Inc. n=516
NCT05286762 COMPLETED
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
Cingulate Therapeutics n=103
NCT06215144 TERMINATED
Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD
Neurocentria, Inc. n=95
NCT06454604 COMPLETED
Virtual Reality Treatment for Emerging Adults With ADHD
Rutgers, The State University of New Jersey n=60
NCT06431256 TERMINATED
Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD
Ironshore Pharmaceuticals and Development, Inc n=26
NCT06854601 COMPLETED
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
Pharmasoft n=333
NCT05631626 COMPLETED
Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.
Cingulate Therapeutics n=21
NCT05924594 SUSPENDED
Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301
Cingulate Therapeutics n=45
NCT02348073 COMPLETED
Efficacy of Phosphatidylserine Enriched With n-3 PUFA Supplementation on ADHD in Children With Epilepsy
Hospices Civils de Lyon n=77
NCT05683249 COMPLETED
Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)
Neurocentria, Inc. n=223
NCT03605849 COMPLETED
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. n=662
NCT03659929 COMPLETED
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
Arbor Pharmaceuticals, Inc. n=320
NCT04569357 COMPLETED
Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children
Materia Medica Holding n=363
NCT02691182 TERMINATED
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
Supernus Pharmaceuticals, Inc. n=491
NCT03597503 TERMINATED
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
Supernus Pharmaceuticals, Inc. n=41
NCT02618434 COMPLETED
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
Supernus Pharmaceuticals, Inc. n=297
NCT04839562 COMPLETED
A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
Massachusetts General Hospital n=66
NCT06006871 COMPLETED
Effectiveness of the Serious Video Game MOON in Emotional Regulation in ADHD
Puerta de Hierro University Hospital n=76
NCT02618408 COMPLETED
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
Supernus Pharmaceuticals, Inc. n=333
NCT03834766 COMPLETED
Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD
Tris Pharma, Inc. n=130
NCT04958460 COMPLETED
Effect of Probiotics on ADHD
Wang Liang-Jen n=150
NCT02502799 TERMINATED
Intervention for Teens With ADHD and Substance Use
Florida International University n=158
NCT04016779 COMPLETED
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
Supernus Pharmaceuticals, Inc. n=374
NCT03481959 TERMINATED
Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity
Assistance Publique - Hôpitaux de Paris n=3
NCT03605680 COMPLETED
A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. n=604
NCT02704390 COMPLETED
Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
Orient Pharma Co., Ltd. n=64
NCT02450890 COMPLETED
Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
Orient Pharma Co., Ltd. n=114
NCT03605836 COMPLETED
A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. n=590
NCT02777931 COMPLETED
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
Aevi Genomic Medicine, LLC, a Cerecor company n=101
NCT03618030 COMPLETED
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Purdue Pharma, Canada n=288
NCT02520388 COMPLETED
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting
Ironshore Pharmaceuticals and Development, Inc n=163
NCT02493777 COMPLETED
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
Ironshore Pharmaceuticals and Development, Inc n=125
NCT03460652 COMPLETED
KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD
Zevra Therapeutics n=282
NCT03247543 COMPLETED
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD
Supernus Pharmaceuticals, Inc. n=313
NCT03247530 COMPLETED
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD
Supernus Pharmaceuticals, Inc. n=477
NCT03247556 COMPLETED
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD
Supernus Pharmaceuticals, Inc. n=297
NCT03292952 COMPLETED
KP415 Classroom Study in Children (6-12 Years of Age) With ADHD
Zevra Therapeutics n=155
NCT03247517 COMPLETED
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
Supernus Pharmaceuticals, Inc. n=310
NCT03260205 COMPLETED
Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Shire n=199
NCT02466425 COMPLETED
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Shire n=264
NCT03325894 TERMINATED
Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Shire n=141
NCT02604407 COMPLETED
Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
Shire n=275
NCT03325881 COMPLETED
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
Shire n=89
NCT02700685 COMPLETED
Effect of Pycnogenol® on ADHD
Nina Hermans n=88
NCT02428088 COMPLETED
Dasotraline Pediatric ADHD Study
Sumitomo Pharma America, Inc. n=330
NCT02466386 COMPLETED
Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder
Shire n=113
NCT03231800 COMPLETED
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Sumitomo Pharma America, Inc. n=95
NCT02734693 COMPLETED
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Sumitomo Pharma America, Inc. n=132
NCT02457819 COMPLETED
Dasotraline Pediatric Extension Study
Sumitomo Pharma America, Inc. n=237
NCT03172481 COMPLETED
PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD
Purdue Pharma, Canada n=156
NCT04016792 WITHDRAWN
Classroom Study of SPN-812 in Children With ADHD
Supernus Pharmaceuticals, Inc.
NCT03088267 COMPLETED
Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study
Tris Pharma, Inc. n=18
NCT02555150 COMPLETED
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
Rhodes Pharmaceuticals, L.P. n=40
NCT02477748 TERMINATED
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
Alcobra Ltd. n=283

Data: ClinicalTrials.gov